Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Group experience

Journal of Clinical Oncology

Volumn 15, Issue 4, 1997, Pages 1544-1552

  Krischer, J P ^a   Epstein, S ^a   Cuthbertson, D D ^a   Goorin, A M ^a   Epstein, M L ^a   Lipshultz, S E ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; MITOXANTRONE;

ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CHILD; CHILDHOOD CANCER; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HEART DEATH; HEART FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

EID: 0030904457     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.4.1544     Document Type: Article

References (70)

1. Hitchcock-Bryan S, Gelber R, Cassady JR, et al: The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia. Med Pediatr Oncol 14:211-215, 1986
2. Smith MA, Ungerleider RS, Hurwitz ME, et al: Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst 83:1460-1470, 1991
3. Burgert EO, Nesbit ME, Garnsey LA, et al: Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: Intergroup Study IESS-II. J Clin Oncol 8:1514-1524, 1990
4. Bleyer WA: The impact of childhood cancer on the United States and the world. CA 40:355-367, 1990
5. Cuthbertson DD, Epstein ST, Lipshultz SE, et al: Anthracycline cardiotoxicity in children with cancer. Circulation 90:I-50, 1994 (abstr)
6. Von Hoff DD, Layard M, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979
7. Lefrak EA, Pitha J, Rosenheim S, et al: Adriamycin (NSC 123127) cardiomyopathy. Cancer Chemother Rep 6:203-208, 1975
8. Sallan SE, Clavell LA: Cardiac effects of anthracyclines used in the treatment of childhood acute lymphoblastic leukemia: A 10 year experience. Semin Oncol 11:19-21, 1984
9. Von Hoff DD, Rozencweig M, Layard M, et al: Daunomycininduced cardiotoxicity in children and adults: A review of 110 cases. Am J Med 62:200-207, 1977
10. Minow RA, Benjamin RS, Lee ET, et al: Adriamycin cardiomyopathy risk factors. CA 39:1397-1402, 1977
11. Minow RA, Benjamin RS, Gottleib JA: Adriamycin (NSC-123127) cardiomyopathy - An overview with determination of risk factors. Cancer Chemother Rep 6:195-201, 1975
12. Hausdorf G, Mork G, Beron G, et al: Long-term doxorubicin cardiotoxicity in childhood: Non-invasive evaluation of the contractile state and diastolic filling. Br Heart J 60:309-315, 1988
13. Goorin AM, Chauvenet AR, Perez-Atayde AR, et al: Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediatr 116:144-147, 1990
14. Lipshultz SE, Colan SD, Gelber RD, et al: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324:808-815, 1991
15. Yeung ST, Yoong C, Spink J, et al: Functional myocardial impairment in children treated with anthracyclines for cancer. Lancet 337:816-818, 1991
16. Weesner KM, Bledsoe M, Chauvenet A, et al: Exercise echocardiography in the detection of anthracycline cardiotoxicity. CA 68:435-438, 1991
17. Steinherz LJ, Steinherz PG, Tan CTC, et al: Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266:1672-1677, 1991
18. Klewer SE, Goldberg SJ, Donnerstein RL, et al: Dobutamine stress echocardiography: A sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer. J Am Coll Cardiol 19:394-401, 1992
19. Larsen RL, Jakacki RI, Vetter VL, et al: Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol 70:73-77, 1992
20. Anonymous: Childhood cancer, anthracyclines, and the heart. Lancet 339:1388-1389, 1992
21. Larsen RL, Barber G, Heise CT, et al: Exercise assessment of cardiac function in children and young adults before and after bone marrow transplantation. Pediatrics 89:722-729, 1992
22. Green DM: Effects of treatment for childhood cancer on vital organ systems. Cancer 71:3299-3305, 1993
23. Leandro J, Dyck J, Poppe D, et al: Cardiac dysfunction late after cardiotoxic therapy for childhood cancer. Am J Cardiol 74:1152-1156, 1994
24. Lipshultz SE, Lipsitz SR, Mone SM, et al: Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332:1738-1743, 1995
25. Sorensen K, Levitt G, Sebag-Montefiore D, et al: Cardiac function in Wilms' tumor survivors. J Clin Oncol 13:1546-1556, 1995
26. Lipshultz SE, Colan SD: The use of echocardiography and Holter monitoring in the assessment of anthracycline-treated patients, in Bricker JT, Green DM, DiAngeo G (eds): Long Term Complications of Treatment of Children and Adolescents for Cancer. Philadelphia, PA, Wiley-Liss, 1993, pp 45-62
27. Lipshultz SE, Sanders SP, Goorin AM, et al: Monitoring for anthracycline cardiotoxicity. Pediatrics 93:433-437, 1994
28. Burrows FA, Hickey PR, Colan S: Perioperative complications in patients with anthracycline chemotherapeutic agents. Can J Anaesth 32:144-157, 1985
29. Braverman AC, Antin JH, Plappert MT, et al: Cyclophosphamide cardiotoxicity in bone marrow transplantation: A prospective evaluation of new dosing regimens. J Clin Oncol 9:1215-1223, 1991
30. Isberg B, Paul C, Jonsson L, et al: Myocardial toxicity of high-dose cyclophosphamide in rabbits treated with daunorubicin. Cancer Chemother Pharmacol 28:171-180, 1991
31. Ayash LJ, Wright JE, Tretyakov O, et al: Cyclophosphamide pharmacokinetics: Correlation with cardiac toxicity and tumor response. J Clin Oncol 10:995-1000, 1992
32. Steinherz LJ, Steinherz PG, Mangiacasale D, et al: Cardiac abnormalities after AMSA administration. Cancer Treat Rep 66:483-488, 1982
33. Weiss RB, Grillo-Lopez AJ, Marsoni S, et al: Amsacrine-associated cardiotoxicity: An analysis of 82 cases. J Clin Oncol 4:918-928, 1986
34. Tan CT, Hancock C, Steinherz PG, et al: Phase II study of 4′-(9-acridiny-lamino) methanesulfon-m-anisidide (NSC 249992) in children with acute leukemia and lymphoma. Cancer Res 42:1579-1581, 1982
35. Krischer J, Land VJ, Civin CI, et al: Evaluation of AMSA in children with acute leukemia. A Pediatric Oncology Group study. Cancer 54:207-210, 1984
36. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
37. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J R Stat Soc 135:185-198, 1972
38. Cox DR: Regression models and life-tables. J R Stat Soc 34:187-220, 1972
39. Altman DG, Lausen B, Sauerbrei W, et al: Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86:829-835, 1994
40. SAS/STAT User's Guide, vol 2, version 6 (ed 4). Cary, NC, SAS Institute, 1990, pp 1027-1069
41. Green D, Zevon M, Lowrie G: Doxorubicin is a significant risk factor for second malignant tumors (SMTs) after treatment for childhood cancer. Proc Am Soc Clin Oncol 14:438, 1995 (abstr)
42. Arlin ZA, Feldman EJ, Mittelman A, et al: Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia. Cancer 68:1198-1200, 1991
43. Lipshultz SE, Sallan SE: Cardiovascular abnormalities in long-term survivors of childhood malignancy. J Clin Oncol 11:1199-1203, 1993
44. Matthys D, Verhaaren H, Benoit Y, et al: Gender difference in aerobic capacity in adolescents after cure from malignant disease in childhood. Acta Pediatr 82:459-462, 1993
45. Silber JH, Jakacki RI, Larsen RL, et al: Increased risk of cardiac dysfunction after anthracyclines in girls. Med Pediatr Oncol 21:477-479, 1993
46. Frisancho AR: Triceps skin fold and upper arm muscle size norms for assessment of nutritional status. Am J Clin Nutr 27:1052-1058, 1974
47. Tanner JM, Whitehouse RH: Revised standards for triceps and subscapular skinfolds in British children. Arch Dis Child 50:142-145, 1975
48. Lee YT, Chan KK, Harris PA: Tissue disposition of doxorubicin in experimental animals. Med Pediatr Oncol 10:259-267, 1982
49. Piazza E, Natale N, Trabattoni A, et al: Plasma and tissue distribution of adriamycin in patients with pelvic cancer. Tumori 67:533-537, 1981
50. Rodvold KA, Rushing DA, Tewksbury DA: Doxorubicin clearance in the obese. J Clin Oncol 6:1321-1327, 1988
51. Bradley G, Georges E, Ling V: Sex-dependent and independent expression of the P-glycoprotein isoforms in Chinese hamster. J Cell Physiol 145:398-408, 1990
52. Dobbs NA, Tewlves CJ, Gillies H, et al: Gender effects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol 36:473-476, 1995
53. Wade JR, Kelman AW, Kerr DJ, et al: Variability in the pharmacokinetics of epirubrein: A population analysis. Cancer Chemother Pharmacol 29:391-395, 1992
54. Eysmann SB, Douglas PS: Coronary heart disease: Therapeutic principles, in Douglas PS (ed): Cardiovascular Health and Disease in Women. Philadelphia, PA, Saunders, 1993, p 57
55. SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293-302, 1991
56. Wenger NK, Speroff L, Packard B: Cardiovascular health and disease in women. N Engl J Med 329:247-256, 1993
57. Couglin SS, Szklo M, Baughman K, et al: The epidemiology of idiopathic dilated cardiomyopathy in a biracial community. Am J Epidemiol 131:48-56, 1990
58. Couglin SS, Labenberg JR, Tefft MC: Black-white differences in idiopathic dilated cardiomyopathy: The Washington, DC dilated cardiomyopathy study. Epidemiology 4:165-172, 1993
59. Couglin SS, Neaton JD, Sengupta A, et al: Predictors of mortality from idiopathic dilated cardiomyopathy in 356,222 men screened for the multiple risk factor intervention trial. Am J Epidemiol 139:166-172, 1994
60. Couglin SS, Gottdiener JS, Baughman KL: Black-white differences in mortality in idiopathic dilated cardiomyopathy: The Washington, DC dilated cardiomyopathy study. J Natl Med Assoc 86:583-591, 1994
61. Khoury M, Erickson D: Improved ascertainment of cardiovascular malformations in infants with Down's syndrome, Atlanta, 1968 through 1989. Am J Epidemiol 136:1457-1464, 1992
62. Kennedy RL, Jones TH, Cuckle HS: Down's syndrome and the thyroid. J Endocrinol 37:471-476, 1992
63. Polikar R, Burger AG, Scherrer U, et al: The thyroid and the heart. Circulation 87:1435-1441, 1993
64. Bland JW Jr, Edwards FK, Brinsfield D: Pulmonary hypertension and congestive heart failure in children with chronic upper airway obstruction. Am J Cardiol 23:830-837, 1969
65. Levine OR, Simpser M: Alveolar hypoventilation and cor pulmonale associated with chronic airway obstruction in infants with Down syndrome. Clin Pediatr 21:25-29, 1982
66. Louglin GM, Wynne JW, Victorica BE: Sleep apnea as a possible cause of pulmonary hyprtension in Down syndrome. J Pediatr 98:435-437, 1981
67. Wilson SK, Hutchins GM, Neill CA: Hypertensive pulmonary vascular disease in Down's syndrome. J Pediatr 95:722-726, 1979
68. Stebbens VA, Dennis J, Samuels MP, et al: Sleep related upper airway obstruction in a cohort with Down's syndrome. Arch Dis Child 66:1333-1338, 1991
69. Cooney TP, Thurlbeck WM: Pulmonary hypoplasia in Down's syndrome. N Engl J Med 307:1170-1173, 1982
70. Cooley WC, Graham JM: Common syndromes and management issues for primary care physicians. Clin Pediatr 4:233-253, 1991